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INTRODUCTION: Hypercholesterolemia is a common finding in primary biliary cirrhosis (PBC), but the risk of
cardiovascular events in PBC patients is not increased in respect to the general population. High
serum adiponectin levels appear to play a protective role in the development of either metabolic
syndrome or cardiovascular disease.
AIM: To investigate factors potentially preventing atherosclerosis in PBC patients.
METHODS: Circulating levels of adiponectin, resistin, leptin, and tumor necrosis factor-alpha (TNF-α) were
measured in 137 consecutive PBC patients (125 women, 12 men; mean age 61.6 ± 12.3 yr), 137
sex- and age-matched healthy controls, and 30 female patients with nonalcoholic steatohepatitis
(NASH) and associated metabolic syndrome.
RESULTS: The body mass index (BMI) was comparable in the three groups, whereas total cholesterol was
significantly higher in both PBC and NASH cases than in controls (221.6 ± 50.5 mg/dL in PBC vs
221.7 ± 39.7 mg/dL in NASH vs 209.8 ± 39.2 mg/dL in controls, P < 0.05). Serum concentrations
of adiponectin, resistin, and leptin were significantly higher in PBC patients than in either NASH
cases or controls (P < 0.05). Among the PBC patients, only adiponectin correlated positively with
histological progression of the disease (P = 0.001) and negatively with BMI (P = 0.01). Logistic
regression analysis revealed that adiponectin correlated independently with age, BMI, Mayo score,
and gamma-glutamyl transpeptidase.
CONCLUSIONS: The high adiponectin concentrations observed in PBC patients should be regarded as a possible
protective factor against atherogenesis. The search for further protective factors should be
encouraged.
(Am J Gastroenterol 2008;103:1959–1965)
INTRODUCTION
Hypercholesterolemia is a common finding in primary bil-
iary cirrhosis (PBC). It is still debated, however, whether hy-
perlipidemia increases the cardiovascular risk and should be
treated. In a cohort of 312 PBC patients observed for 7.4 yr,
the incidence of atherosclerotic diseases was not statistically
different when compared with age-matched and sex-matched
controls (1). In an Italian cohort of 400 PBC patients followed
up for 6.2 yr, marked hypercholesterolemia, typical of se-
vere long-standing cholestasis, was not associated with any
increased risk of vascular disease (2). The same Italian re-
searchers recently conducted ultrasound imaging studies on
the carotid artery of 103 PBC patients (38% of them with hy-
percholesterolemia), 37 controls with hypercholesterolemia,
and 141 matched controls with normal cholesterol. Con-
trols with hypercholesterolemia, but not PBC patients with
high serum cholesterol, had increased risk of intima-media
thickness. These results suggest that hypercholesterolemia is
not consistently associated with subclinical atherosclerosis
in PBC (3), though no putative protective factors have been
studied specifically as yet in PBC.
It has recently been claimed that adipose tissue takes a
metabolically active part in mediating vascular complica-
tions (4). Adipose tissue is a part of the endocrine system and
acts as an active endocrine and paracrine organ secreting a
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number of mediators (known as adipokines) involved in
various metabolic processes (5). These factors include
adiponectin, leptin, resistin, tumor necrosis factor-alpha
(TNF-α), complement components, plasminogen activator
inhibitor-1, and proteins of renin–angiotensin system.
Adiponectin is the most abundant of the factors known to
be secreted. It is produced by the adipocytes and has several
functions. In particular, it acts as an antiatherogenic factor
by inhibiting the conversion of macrophages into foam cells,
as an antidiabetic factor by increasing insulin sensitivity and
reducing gluconeogenesis, and as an anti-inflammatory fac-
tor by inhibiting the hepatic synthesis of TNF-α (6). Plasma
adiponectin levels have also been shown to correlate with sur-
rogate markers of atherosclerosis. Low plasma adiponectin
levels are associated with the progression of subclinical
coronary atherosclerosis. Adiponectin also affords protection
against atherosclerosis and metabolic syndrome (7). Leptin
has several effects on energy homeostasis (8). Although it was
initially considered an antiobesity hormone, its primary role
is to serve as a metabolic signal of energy sufficiency rather
than excess (9). Resistin is a 12 kDa polypeptide that inter-
feres with insulin homeostasis. In vivo treatment with recom-
binant resistin induces insulin resistance in rodents, whereas
immune neutralization of resistin has the opposite effect (10).
In vivo studies have suggested an association between high re-
sistin levels and glucose intolerance, hyperinsulinemia, and a
limited suppression of fatty acids (11). Finally, TNF-α is a key
cytokine involved in several metabolic processes including
the repression of genes involved in both glucose metabolism
and fatty acid oxidation (12, 13). TNF-α and adiponectin in-
teract in various biological systems. These two key mediators
control each other’s synthesis and activity, thereby ensuring
a physiological balance. They may have a key role in dis-
eases associated with insulin resistance in which this critical
balance may be impaired, leading to chronic inflammation
(14).
The aim of the present study was to investigate factors
potentially preventing atherosclerosis in PBC patients.
MATERIAL AND METHODS
Patients
The study was conducted on patients being followed up at
three Italian referral centers (Padua University, Turin Uni-
versity, and San Giovanni Rotondo Hospital), i.e.,
1. In total, 137 consecutive PBC patients (12 men, 125
women; mean age 61.6 ± 12.3 yr);
2. In total, 30 consecutive female patients with nonalcoholic
steatohepatitis (NASH) with associated metabolic syn-
drome (mean age 49.9 ± 3.7 yr).
One hundred and thirty-seven healthy insulin-sensitive
subjects (Homeostasis Model Assessment Score for Insulin
Resistance [HOMA-IR] <2 mmol/L × µU/mL), matched
for sex and class of age with PBC patients (mean age 60.2 ±
10.4 yr), served as controls. The study was approved by the
local ethical committee, and all subjects gave their informed
consent to their participation in the study.
The diagnosis of PBC was based on an antimitochondrial
antibody titer of at least 1:40, abnormal liver function tests,
and a diagnostic or compatible liver biopsy. The Mayo score,
based on a combination of five variables (bilirubin, age, albu-
min, prothrombin time, and severity of edema) was calculated
for each patient (15). The standard treatment consisted of ur-
sodeoxycholic acid (15 mg/kg/day) in divided doses given
after meals.
The diagnosis of NASH was considered in the presence of
chronic hypertransaminasemia and bright liver at ultrasound,
in the absence of any putative cause of liver disease. The
presence of metabolic syndrome was diagnosed according to
the Adult Treatment Panel III criterion (16). In all subjects,
liver biopsy was diagnostic for NASH, according to Brunt et
al. (17), on the basis of the presence of fibrosis (grade 1 or
higher) or necroinflammation (grade 2 or higher).
Fasting glucose and insulin levels were used to calculate
insulin resistance according to the HOMA technique (18).
Laboratory Analysis
Serum adiponectin, leptin, and TNF-α were measured by
sandwich enzyme-linked immunosorbent assays (R&D Sys-
tem Europe, Ltd., Abingdon, U.K.). All samples were diluted
1:100. For human adiponectin, the kit has a sensitivity of
0.25 pg/mL in a 50-µL sample size and a range of 3.9–250.0
ng/mL. The intra- and interassay coefficients of variations
(CVs) were 3.4% and 5.8%, respectively.
For human leptin, the kit has a sensitivity of less than
7.8 pg/mL in a 50-µL sample size and a range of 15–1,000
pg/mL. The intra- and interassay CVs were 3.0% and 4.2%,
respectively. For TNF-α, the kit has a sensitivity of 0.12
pg/mL in a 200-µL sample size and a range of 0.5–32.0
pg/mL. The intra- and interassay CVs were 5.9% and 12.6%,
respectively.
Resistin was measured by a biotin-labeled antibody-based
sandwich enzyme immunoassay (Bio Vendor Laboratory
Medicine, Inc., Brno, Czech Republic). The intra-assay and
interassay CVs were 2.8–3.4% and 5.5–6.8%, respectively.
Statistical Analysis
Data are summarized as frequencies and percentages for cat-
egorical data and as means ± standard deviation (SD) for
continuous data. Analyses were performed using the χ2 test
or Fisher’s exact test, one-way analysis of variance (ANOVA),
linear logistic analysis, and Student’s t-test adjusted for the
Bonferroni correction as appropriate. A multivariate logis-
tic regression analysis was conducted in the PBC group
to identify variables independently associated with a serum
adiponectin level ≥ 1,600 µg/L (75th percentile of the PBC
sample). A P value of ≤ 0.05 was considered significant. The
analyses were carried out using the Statistical Package for the
Social Sciences (SPSS, Chicago, IL).
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RESULTS
The clinical and biochemical details of patients are listed
in Table 1. Body mass index (BMI) was comparable in all
groups. Total cholesterol was significantly higher in both PBC
and NASH patients than in controls (221.6 ± 50.5 mg/dL in
PBC vs 221.7 ± 39.7 in NASH vs 209.8 ± 39.2 in controls,
P < 0.05).
Figure 1 shows the serum concentrations of adiponectin,
resistin, leptin, and TNF-α expressed as mean ± SD in the
study groups and healthy controls. Adiponectin was signif-
icantly higher in PBC patients compared to either NASH
patients or controls (14,338 ± 12,221 ng/mL vs 6,941 ±
4,386 ng/mL vs 7,092 ± 4,637 ng/mL, P < 0.02). Serum
adiponectin levels were similar in NASH patients and in con-
trols (P = NS). Serum leptin was significantly higher in PBC
patients than in controls (17,411 ± 17,936 ng/mL vs 8,177
± 10,222 ng/mL, P < 0.05), whereas no significant differ-
ence emerged in the leptin serum concentrations between
PBC and NASH patients. Serum resistin was significantly
higher in PBC patients than in either NASH patients or con-
trols (7.28 ± 4.70 ng/mL vs 3.30 ± 1.21 ng/mL vs 3.45 ±
1.22 ng/mL, P < 0.05), whereas no significant difference in
serum resistin levels was found between NASH patients and
controls (P = NS). Serum TNF-α was slightly increased in
PBC patients, but there was no significant difference among
the three groups.
Comparing the NASH subjects with a group of 30 PBC
patients (selected from the 137 PBC study group) matched
for age, sex, and degree of liver fibrosis, the serum levels
of adiponectin and resistin were significantly higher in PBC
than in NASH patients, whereas no significant difference was
Table 1. Clinical Details of the Study Groups (Biochemical Param-
eters Are Expressed as Mean ± SD)
PBC NASH P Value
Number 137 30
Age (yr) 61.6 ± 12.3 49.9 ± 3.7 <0.001
M/F 12/125 0/30 NS
BMI 25.1 ± 4.5 24.5 ± 2.8 NS
AST (U/L) 49.1 ± 29.6 32.9 ± 13.1 NS
ALT (U/L) 53.3 ± 36.8 66.3 ± 15.8 NS
GGT (U/L) 129.6 ± 121.6 86.9 ± 14.8 NS
ALP (U/L) 335.1 ± 302.6 86.6 ± 33.3 <0.001
Total bilirubin (µmol/L) 0.78 ± 0.63 0.88 ± 0.31 NS
Cholesterol (mg/dL) 221.6 ± 50.5 221.7 ± 39.7 NS
Triglycerides (mg/dL) 115.9 ± 40.8 146.2 ± 79.1 0.03






Normal values: AST (aspartic aminotransferase) <35 U/L; ALT (alanine aminotrans-
ferase) <40 U/L; GGT (gamma-glutamyl transpeptidase) <65 U/L; ALP (alkaline
phosphatase) <115 U/L; total cholesterol <190 mg/dL; triglycerides <140 mg/dL;
total bilirubin <1.2 mg/dL; glucose 110 mg/dL.
P value adjusted for the Bonferroni test.
found in either serum leptin or TNF-α between the two groups
(Table 2).
In the PBC group, there was a significant increase in serum
adiponectin with advancing histological stage (f = 5.88,
P = 0.001), whereas there was a negative correlation between
adiponectin and BMI (r2 = 0.061, P = 0.01).
Logistic regression analysis, performed in patients with
PBC, showed that higher adiponectin level was independently
correlated to age (adjusted OR 1.043, 95% CI 1.002–1.086,
P = 0.042), BMI (adjusted OR 0.379, 95% CI 0.149–0.963,
P = 0.041), Mayo score (adjusted OR 1.764, 95% CI 1.146–
2.716, P = 0.042), and gamma-glutamyl transpeptidase
(GGT) (adjusted OR 0.340, 95% CI 0.135–0.853, P = 0.022)
(Table 3).
DISCUSSION
The results of our study indicate that adiponectin, resistin,
and leptin, but not TNF-α, are significantly higher in the
sera of PBC patients than in either NASH patients or healthy
controls. In our PBC patients, only adiponectin was asso-
ciated with histological progression and it correlated nega-
tively with BMI. Moreover, logistic regression analysis re-
vealed that adiponectin correlated independently with age,
Mayo score, and GGT. These results prompt several consid-
erations.
First of all, hypercholesterolemia is a clinical problem in
PBC, but judging from preliminary studies (1–3), it should
not be regarded as a risk factor for cardiovascular disease in
PBC. The search for factors protecting against endothelial
damage is still on, however. Our study paves the way to fur-
ther research to demonstrate whether adiponectin has a key
role in this sense. Serum adiponectin was found significantly
higher than normal in 20 cirrhotic patients and it correlated
with liver function impairment and altered hepatic hemody-
namics (19). In another article, Tacke et al. compared 111
chronic liver disease patients (mostly cirrhotic with different
etiology) and 226 healthy controls (20) and found adiponectin
significantly elevated in cirrhotic patients, correlating with
the stage of liver cirrhosis, liver cell injury, and biochemi-
cal markers of cholestasis (20). Interestingly, the same au-
thors (20) found a 2- to 3-fold increase in serum adiponectin
in an experimental model of bile duct ligation. They mon-
itored hepatic adiponectin gene expression in this experi-
mental model, thereby confirming that the increase in serum
adiponectin was due to decreased biliary secretion of adipose
tissue-derived adiponectin, rather than due to a stimulation
of hepatic production of adiponectin. In this light, because
biliary secretion is involved in the clearance of adiponectin,
progressive cholestasis may favor the intrahepatic accumu-
lation of adiponectin. In this view, the increasing levels of
this adipokine with the progression of the disease might be
interpreted as an adaptative phenomenon to cholestasis.
Moreover, as the progression of PBC is very slow (21),
the accumulation of this hepatoprotective hormone could
1962 Floreani et al.
Figure 1. Serum levels of adipokines in PBC and NASH patients and healthy controls.
potentially contribute to the long natural history of this
disease. This hypothesis needs further study, however, be-
cause the hepatoprotective role of adiponectin has only
been established in experimental studies, not in humans
(22, 23). Nevertheless, recent evidence convincingly demon-
strated that adiponectin profoundly interacts with the im-
mune/macrophage system and might be of relevance in many
liver diseases (24).
The protective role of adiponectin in relation to the de-
velopment of atherosclerosis is well known (25). The no-
tion that plasma adiponectin concentrations are lower in pa-
tients with coronary artery disease supports the concept that
adiponectin could somehow protect against atherosclerosis
(26). Adiponectin modulates endothelial function and in-
hibits proliferation of vascular smooth muscle cells induced
by growth factors (27). It also has an in vitro inhibitory ef-
fect on TNF-α-induced monocyte adhesion and adhesion
molecule expression (28). Adiponectin-deficient mice re-
cently showed twice as much neointimal formation in re-
sponse to external injury as wild-type mice (29).
The lower adiponectin levels in NASH patients compared
to either PBC patients or controls confirm the results obtained
in previous studies (30, 31), where adiponectin was inversely
correlated with liver steatosis, but the correlation between
adiponectin and insulin resistance and fibrosis has yet to be
fully clarified. However, comparing the NASH subjects with
a group of PBC patients matched for age, sex, and degree of
liver fibrosis, adiponectin serum levels were still significantly
higher in PBC than in NASH patients.
Serum leptin was found significantly higher in PBC than
in either NASH cases or controls, thereby suggesting some
intriguing hypotheses. In fact, studies performed in cirrhotic
patients from different aetiologies have shown that serum
leptin tends to rise in cirrhosis, especially in the early stages
(32–35); but in this complex setting, the higher serum con-
centrations are probably due to this hormone’s involvement in
fibrogenesis (36–38), rather than due to atherosclerosic pro-
cesses. Indeed, the association between leptin and coronary
artery calcification was examined by Reilly et al. (39), who
found an association between plasma leptin and coronary
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Table 2. Clinical Details of the Study Groups (Biochemical Parameters Are Expressed as Mean ± SD)
PBC∗ NASH P Value
Number 30 30
Age (yr) 50.8 ± 4.5 49.9 ± 3.7 NS
BMI 25.1 ± 4.4 24.5 ± 2.8 NS
AST (U/L) 36.4 ± 23.6 32.9 ± 13.1 NS
ALT (U/L) 48.8 ± 40.7 66.3 ± 15.8 NS
GGT (U/L) 92.0 ± 66.4 86.9 ± 14.8 NS
ALP (U/L) 271.9 ± 286.7 86.6 ± 33.3 0.01
Total bilirubin (µmol/L) 0.67 ± 0.35 0.88 ± 0.31 NS
Cholesterol (mg/dL) 226.8 ± 52.4 221.7 ± 39.7 NS
Triglycerides (mg/dL) 120.1 ± 40.2 146.2 ± 79.1 NS
Glucose (mg/dL) 103.2 ± 24.0 82.2 ± 7.7 0.02
Adiponectin (ng/mL) 11,493.1 ± 7,005.7 6,941.3 ± 4,348.6 0.04
Leptin (ng/mL) 25,992.2 ± 29,051.3 12,529.8 ± 12,835.8 NS
Resistin (ng/mL) 6.1 ± 4.3 3.3 ± 1.2 0.01






Normal values: AST (aspartic aminotransferase) <35 U/L; ALT (alanine aminotransferase) <40 U/L; GGT (gamma-glutamyl transpeptidase) <65 U/L; ALP (alkaline phosphatase)
<115 U/L; total cholesterol <190 mg/dL; triglycerides <140 mg/dL; total bilirubin <1.2 mg/dL; glucose 110 mg/dL.
P value adjusted for the Bonferroni test.
∗This group is a part of the 137 PBC study group.
atherosclerosis in type 2 diabetes. Moreover, in a recent arti-
cle by Singhal et al. (40), 294 healthy adolescents underwent
brachial artery distensibility measurement; higher leptin lev-
els were associated with impaired vascular function, irrespec-
tive of any metabolic or inflammatory conditions associated
with obesity. The hypothesis that leptin has an independent
influence on vessel health is supported by recent prospective
observations that leptin is an independent risk factor for coro-
nary events (41, 42). Paradoxically, these observations do not
seem to apply to liver disease patients. In PBC patients, in
particular, we failed to find any correlation between leptin
and either BMI or severity of liver disease. Further studies
are warranted, however, to investigate the effect of chronic
hyperleptinemia on vascular function.
Table 3. Multivariate Analysis of Risk Factors Associated to High Level of Adiponectin in PBC Patients
95.0% CI for Adjusted OR
Variable Adjusted OR Lower Upper P Value
Age (continuous variable) 1.043 1.002 1.086 0.042
BMI (≥25.0 vs <25.0) 0.379 0.149 0.963 0.041
Mayo score (continuous variable) 1.764 1.146 2.716 0.010
Stage (continuous variable) 1.422 0.869 2.326 0.161
AST (abnormal vs normal) 1.634 0.548 4.877 0.379
ALT (abnormal vs normal) 0.640 0.218 1.885 0.418
GGT (abnormal vs normal) 0.340 0.135 0.853 0.022
ALP (abnormal vs normal) 2.756 0.713 10.657 0.142
Total cholesterol (abnormal vs normal) 1.440 0.472 4.389 0.522
Triglycerides (normal vs abnormal) 1.086 0.387 3.051 0.875
Total bilirubin (abnormal vs normal) 1.108 0.303 4.047 0.877
Glucose (abnormal vs normal) 1.619 0.598 4.386 0.343
Normal values: AST (aspartic aminotransferase) <35 U/L; ALT (alanine aminotransferase) <40 U/L; GGT (gamma-glutamyl transpeptidase) <65 U/L; ALP (alkaline phosphatase)
<115 U/L); total cholesterol <190 mg/dL; triglycerides <140 mg/dL; total bilirubin <1.2 mg/dL; glucose 110 mg/dL.
The same considerations apply to serum resistin concentra-
tion. Circulating resistin levels are increased in mouse models
of obesity and in obese humans and are involved in the patho-
genesis of diabetic complications (43). The source of resistin,
however, is currently being debated, (44), and resistin release
appears to be stimulated by inflammation, LPS (lipopolysac-
charide), IL (interleukin)-6, hyperglicemia, and growth and
gonadal hormones (43).
Finally, TNF-α revealed no differences between PBC pa-
tients and either NASH cases or healthy controls. TNF-α is a
complex cytokine that may have numerous effects in cholesta-
sis (45). In general, its levels tend to be higher in histologi-
cally more advanced stages than in early stages, but they de-
cline under UDCA (ursodeoxycholic acid) therapy (46). All
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patients with PBC were on UDCA, so we could not expect to
see any significant variation in TNF-α levels.
In conclusion, the high concentration of adiponectin seen
in PBC patients suggests that it should be regarded as a likely
protective factor against atherogenesis. The search for further
factors should be encouraged.
STUDY HIGHLIGHTS
What Is Current Knowledge
 Hypercholesterolemia is a common finding in primary
biliary cirrhosis (PBC), but the risk of cardiovascular
events is not increased in respect to the general popu-
lation.
 No putative protective factors have been studied specif-
ically as yet in PBC.
What Is New Here
 Serum concentration of adiponectin, resistin, and leptin
are significantly higher in PBC patients than in either
NASH cases or healthy controls. Among the PBC pa-
tients, only adiponectin correlates positively with the
disease progression and negatively with body mass in-
dex (BMI).
 Logistic regression analysis reveals that adiponectin
correlates independently with age, BMI, Mayo score,
and gamma-glutamyl transpeptidase.
 The high adiponectin concentration should be regarded
as a possible protective factor against atherosclerosis.
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